COYA — Coya Therapeutics, Inc.
Is COYA overbought or oversold? Here is the current MarketMoodz read.
Coya Therapeutics, Inc. (COYA) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $3.00. The rating moved from Oversold to Neutral on November 13, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$3.00
- Last changeMoved from Oversold to Neutral on November 13, 2026
- SectorHealthcare
- IndustryBiotechnology
AI analysis
With limited company-specific disclosure in the provided data, near-term prospects hinge on financing status and any upcoming clinical or corporate catalysts. Market tone is modestly supportive for growth-oriented names, but rotation toward large-cap pharma and noted sector dilution pressures constrain upside. Key drivers to watch are cash runway, binary clinical readouts or licensing activity; primary downside stems from the need for dilutive financing, clinical/regulatory setbacks, and low liquidity that can magnify negative news.
Key factors
- Limited public financial disclosure in the provided dataset, making assessment of cash runway and burn dependent on external filings
- Macro/market tone is risk-on and growth-favoring, which can support small-cap biotech rallies on positive news or trial readouts
- Sector dynamics: rotation into large-cap pharma and defensive flows may limit near-term speculative capital for smaller biotechs
- Convertible-debt and financing environment in mid-cap biotech is highlighted as a source of dilution pressure across the sector
- Potential upside from clinical readouts, partnerships, licensing or M&A interest in niche therapeutic platforms
- Low liquidity and retail attention typical for smaller biotech names can amplify volatility around news
Risks
- Unknown or constrained cash runway that could force dilutive financing (equity issuance or convertible debt)
- Clinical development risk: trial delays, negative data or regulatory setbacks can materially reduce valuation
- Competitive pressure from large-cap pharma and faster-to-market competitors in relevant therapeutic areas
- Sector-wide headwinds such as tightening risk appetite or reduced biotech capital flows
- Low free float and thin trading volumes that can create outsized price moves and poor execution for investors
- Limited available social or analyst coverage increases information asymmetry and uncertainty
See today's live rating, score and targets
Members see the live hourly rating for COYA — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.